VanEck Fabless Semiconductor ETF (NASDAQ: SMHX)

Dernières nouvelles pour VanEck Fabless Semiconductor ETF (NASDAQ:SMHX)

The Fund normally invests at least 80% of its total assets in securities that comprise the Funds benchmark index. The Fabless Index is composed of U.S.-listed common stocks of companies that derive at least 50% of their revenues from the semiconductor industry and operate as fabless semiconductor companies. A fabless semiconductor company is generally defined as an advanced chip designer without a production line. More specifically, a fabless semiconductor company is engaged in the design and sale of semiconductors and hardware while outsourcing most semiconductor fabrication and product manufacturing. Furthermore, the Fabless Index does not currently include companies engaged in the production of equipment used in the manufacturing of semiconductors or semiconductor materials used in visual displays

VanEck Fabless Semiconductor ETF

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CASH

Heritage Distilling Board Approves Bitcoin Treasury Policy

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini –
-- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) –
-- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out --
-- Year end, unaudited, cash balance of $835 million following oversubscribed public offering in December 2024 --
NAARDEN, The Netherlands and MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today provided an update on the obicetrapib clinical development program and outlined its strategic priorities for 2025.
NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.&nbsp;The Company's global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients.

Biotech

News

Guidance

General

NAMS

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT & REMBRANDT Trials To Conclude In 2025, 2027.

INSM

Insmed Provides Outlook Ahead Of J.P. Morgan Healthcare Conference; Sees 2025 Global ARIKAYCE Revenues $405M-$425M

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19%
Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023
BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net FUROSCIX revenue and unaudited cash and cash equivalents.

Earnings

SCPH

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

HURC

Hurco Cos Q4 EPS $(0.23) Down From $0.36 YoY, Sales And Service Fees $53.7M Down From $66.11M YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">89.2000</td>
<td align="right">1.17</td>
<td align="right">1.32</td>
<td>33.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.3900</td>
<td align="right">0.38</td>
<td align="right">0.49</td>
<td>13.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">223.3000</td>
<td align="right">0.29</td>
<td align="right">0.13</td>
<td>603</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">140.5199</td>
<td align="right">0.09</td>
<td align="right">0.06</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">232.4200</td>
<td align="right">-1.460</td>
<td align="right">-0.63</td>
<td>23.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.2736</td>
<td align="right">-0.216</td>
<td align="right">-0.45</td>
<td>91.7K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 10, 2025

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $93 to $102.

Price Target

Analyst Ratings

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Raises Price Target to $102

Genius Group Adds $5M To Bitcoin Treasury

ARCT

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

Current Co-Chairman of the Board will now also serve as Chief Executive Officer
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nano-PFA or nsPFA&#x2122;) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

Management

PLSE

Pulse Biosciences Appoints Paul LaViolette As Chief Executive Officer

TYRA

Tyra Biosciences Receives IND Clearance From The FDA To Proceed With A Phase 2 Study Of TYRA-300 In Non-Muscle Invasive Bladder Cancer

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Reiteration

KMDA

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

Contracts

Nano Labs Subsidiary Nano Bit, BitFi Enter Strategic Partnership; Nano Labs Agrees To Adopt Bitcoin As A Long-Term Strategic Reserve Asset, With Nano Bit Responsible For The Management And Operation Of These Assets

RVTY

Revvity Receives FDA Clearance For EUROIMMUN's Free Testosterone Test

TLSA

Tiziana Life Sciences Announced Findings On Benefits Of Its Nasal Anti-CD3 Monoclonal Antibody In Sustaining Tissue Homeostasis And Mitigating The Side Effects Associated With GLP-1 Agonists Discontinuation

<ul>
<li>Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025</li>
<li>Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified</li>
<li>Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site</li>
<li>Future operations will be focused at the U.S. site in Germantown, Maryland</li>
</ul>
OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.

BRNS

Barinthus Bio Restructures, Prioritizes VTP-1000 For Celiac Disease With Phase 1 Data In Mid-2025, Pauses VTP-300 For Hepatitis B Pending Partner; Cuts 65% Workforce, Closes U.K. Site To Extend Cash To 2027 With $112M Reserves; Focuses U.S. Operations In Germantown

Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped over 40% in premarket after it announced a breakthrough in its True All-Solid-State <a href="https://www.benzinga.com/topic/batterie">Battery</a> (ASSB) technology. Technical analysis shows strong support for the stock performance.
What Happened: Unlike conventional batteries, Microvast&#8217;s ASSB eliminates liquid electrolytes, enabling high-voltage operation and simplifying system architecture.
&#8220;Our solid-state battery innovation represents a significant leap forward in addressing real-world safety and efficiency challenges,&#8221; stated CEO Yang Wu.
The press release lists the new battery&#8217;s key features, which include enhanced safety and efficiency along with bipolar stacking architecture, which helps achieve high voltages unattainable by liquid-based batteries. The proprietary all-solid electrolyte separator in the battery ensures conductivity and structural stability.
See Also:<a href="https://www.benzinga.com/25/01/42908280/intel-aims-for-cpu-market-share-growth-ai-breakthroughs-citi-reiterates-neutral-as-new-ceo-appointment-expected-in-coming-months"> Intel Stock Has Fallen Over 58% In 1 Year, But Citi Maintains &#8216;Neutral&#8217; Rating On Expected Replacement Of Pat Gelsinger In A &#8216;Couple Of Months&#8217; </a>
Why It Matters: Microvast&#8217;s ASSB technology is poised to transform various sectors according to the company. This technology will be helpful in data centers, electric vehicles, and advanced robotics, as it offers customized solutions with high energy density and improved safety.
Microvast was up 44.39% at $2.7 in premarket during the publication of this article. It ended 10.95% lower in Wednesday&#8217;s session. The shares have risen by a staggering 345.24% over the last six months and 61.21% over the last year. Nasdaq Composite underperformed the stock as it rose 4.46% in the last six months and 30.1% over the last year.
Technical analysis of daily moving averages with the help of <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> shows strong support for the stock in both the near and long term.
Mirovast&#8217;s shares in premarket trade were above its eight-day simple moving average of $2.29 and its 20-day average of $1.87 apiece, showing strong support in the near term.
The 50 and 200-day simple moving averages were also below the share price at $1.13 and $0.57, respectively, suggesting a bullish uptrend.
On the other hand, the relative strength index of 62.97 suggested that the stock could be moderately overbought but still in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png" alt="" class="wp-image-727887" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42893264/charlie-mungers-top-pick-costco-reports-strong-december-sales-analysts-expect-a-7-jump-in-january">Charlie Munger&#8217;s Top Pick Costco Reports Strong December Sales: Analysts Expect A 7% Jump In January</a> 
According to <a href="https://www.benzinga.com/quote/MVST/analyst-ratings">Benzinga</a>, MVST has a consensus price target of $4.4 per share based on the ratings of five analysts. The highest price target out of all the analysts tracked by Benzinga is $8 apiece issued by Cantor Fitzgerald as of Dec. 18. The lowest target price is $3 per share issued by HC Wainwright &amp; Co. on Nov. 18.
The average recent price target between HC Wainwright &amp; Co. and Janney Montgomery Scott implies a 24.22% upside for MVST.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/MVST/analyst-ratings"><img loading="lazy" decoding="async" width="945" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png" alt="" class="wp-image-727883" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png 945w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-768x289.png 768w" sizes="(max-width: 945px) 100vw, 945px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">California Wildfires Ignite Concerns For Insurance Stocks: Here Are Some Insurance ETFs Which Could Be Impacted </a></li>
</ul>
Image courtesy of Microvast

Analyst Color

Equities

Market Summary

Technicals

Trading Ideas

MVST

Microvast's Breakthrough In All-Solid State Battery Tech Propels Shares To Over 40% In Premarket: Here's What Technical Analysis Says

TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $3.05 by 1.31 percent. The company reported quarterly sales of $15.845 billion which beat the analyst consensus estimate of $15.220 billion by 4.11 percent. This is a 9.98 percent increase over sales of $14.407 billion the same period last year.

Earnings Beats

TD Synnex Q4 2024 Adj. EPS $3.09 Beats $3.05 Estimate, Sales $15.845B Beat $15.220B Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy and maintains $38 price target.

PVLA

HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target

Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, DKK 1 nominal value (the "ADS ratio"), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the "ADS ratio change").
The ADS ratio change is expected to become effective on or about January 14, 2025, U.S. Eastern Time (the "effective date"). Previously, Evaxion planned for the ADS ratio change to become effective on or about January 13, 2025. The date has been extended by one day as Nasdaq Capital Markets was closed on January 9, 2025, in order to observe the passing of President Jimmy Carter. This was not known when Evaxion announced the initial effective date.
For the company's ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split and is intended to further support the liquidity in the company's ADSs.

Stock Split

EVAX

Evaxion Announces Extension To January 14, 2025, Of Plan To Implement ADS Ratio Change From The Current One 1 ADS Representing 10 Ordinary Share To A New ADS Ratio Of 1 ADS Representing 50 Ordinary Shares

Comments

VanEck Fabless Semiconductor ETF

Actualités

Dernières nouvelles pour VanEck Fabless Semiconductor ETF (NASDAQ:SMHX)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL